Shares of medical technology company Integer Holdings (NYSE:ITGR)
fell 8.3% in the afternoon session after the company reported second-quarter results that featured a slight miss on a key profitability metric, which overshadowed a revenue beat and raised profit guidance.
Medical technology company Integer Holdings (NYSE:ITGR) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 11.4% year on year to $476.5 million. The company expects the full year’s revenue to be around $1.86 billion, close to analysts’ estimates. Its non-GAAP profit of $1.55 per share was in line with analysts’ consensus estimates.
Looking back on medical devices & supplies - specialty stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Integer Holdings (NYSE:ITGR) and its peers.
A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like Elevance Health and Humana seeing declines due to an analyst downgrade and a lost lawsuit regarding Medicare bonus payments, respectively.
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names.
But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,
and over the past six months, the industry has pulled back by 13.2%. This drawdown was noticeably worse than the S&P 500’s 2.4% loss.
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential.
However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
Medical technology company Integer Holdings (NYSE:ITGR) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 7.3% year on year to $437.4 million. The company expects the full year’s revenue to be around $1.86 billion, close to analysts’ estimates. Its non-GAAP profit of $1.31 per share was 5.5% above analysts’ consensus estimates.
Medical technology company Integer Holdings (NYSE:ITGR) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 7.3% year on year to $437.4 million. The company expects the full year’s revenue to be around $1.86 billion, close to analysts’ estimates. Its non-GAAP profit of $1.31 per share was 5.5% above analysts’ consensus estimates.
